Imugene (IMU) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock IMU Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Imugene Limited Announces Director’s Interest ChangeJuly 23 at 4:35 AM | tipranks.comImugene Limited Expands Market Presence with New Securities QuotationJuly 23 at 3:48 AM | tipranks.comImugene Limited Announces Quotation of New Securities on ASXJuly 16, 2025 | tipranks.comWednesday's HotCopper trends: Imugene cap raise, Lumos distribution deal | July 16July 15, 2025 | msn.comWhy Imricor, Imugene, Newmont, and Pepper Money shares are falling todayJuly 15, 2025 | msn.comImugene Reports Strong Results for Azer cel in DLBCL TrialJuly 15, 2025 | msn.comImugene Ltd: Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCLJuly 14, 2025 | finanznachrichten.deImugene Reports Strong Results for Azer-cel in DLBCL TrialJuly 14, 2025 | msn.comImugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCLJuly 14, 2025 | finance.yahoo.comImugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic ...July 14, 2025 | gurufocus.comSmall Cap Watch: Imugene’s new data; Lithium Energy’s acquisition; Ionic Rare Earths funding and St George Mining’s niobium potentialJuly 13, 2025 | proactiveinvestors.com.auMonday's HotCopper trends: Imugene responses, Trigg upgrade | July 14July 13, 2025 | msn.comImugene Reports Positive Results in Phase 1b CAR T Trial for DLBCLJuly 13, 2025 | tipranks.comImugene Limited Initiates Trading Halt for Capital Raising AnnouncementJuly 13, 2025 | tipranks.comImugene preps to dazzle market with new clinical data, cash callJuly 13, 2025 | afr.comImugene Secures $5.8 Million R&D Tax Refund to Advance Cancer TherapiesJuly 3, 2025 | tipranks.comImugene’s Resolutions Passed at Extraordinary General MeetingJune 25, 2025 | tipranks.comPaul A. Hopper - IMU.AU | Imugene Ltd. - Wall Street JournalJune 25, 2025 | wsj.comImugene Secures US Patent for Oncolytic Virotherapy, Strengthening Global IP PositionJune 17, 2025 | tipranks.comImugene Limited Announces Cessation of SecuritiesJune 6, 2025 | tipranks.comHealth Check: Stuck in biotech’s ‘death zone’, Opthea and Patrys check in on the sat phoneJune 1, 2025 | msn.comImugene Launches Phase II Trial for PD1-Vaxx in Colorectal CancerJune 1, 2025 | tipranks.comImugene Appoints Dr. John Byon as Chief Medical Officer to Advance Cancer ImmunotherapyMay 29, 2025 | tipranks.comImugene Issues Addendum to Extraordinary General Meeting NoticeMay 27, 2025 | tipranks.comImugene Limited Announces Extraordinary General Meeting for June 2025May 26, 2025 | tipranks.comHotCopper Highlights Week 21: Trump jump for uranium; James Hardie, Imugene & moreMay 23, 2025 | msn.comImugene Limited Issues New Equity Securities as Part of Employee Incentive SchemeMay 23, 2025 | tipranks.comImugene Limited Announces Cessation of SecuritiesMay 21, 2025 | tipranks.comHotCopper Highlights, Week 18: Imugene's letter to investors; Dimerix & DatelineMay 2, 2025 | msn.comImugene Addresses Shareholder Concerns Amidst Market ChallengesApril 30, 2025 | tipranks.comImugene Limited Announces Quotation of New Securities on ASXApril 14, 2025 | tipranks.comWednesday’s HotCopper Trends: Imugene scores FDA tick, Arizona kicks off share purchase plan | March 19, 2025March 19, 2025 | msn.comGuess which ASX stock is surging 11% on big US FDA newsMarch 18, 2025 | msn.comImugene’s Azer-cel Receives FDA Fast Track Designation for DLBCLMarch 18, 2025 | tipranks.comImugene Limited Reports Progress in Cancer TherapiesMarch 9, 2025 | tipranks.comImugene Appoints Darren Keamy as CFO and Company SecretaryMarch 3, 2025 | tipranks.comImugene secures CD19 oncolytic virus patent in ChinaFebruary 26, 2025 | au.investing.comImugene secures patent protection in India for CF33 oncolytic virotherapy technologyFebruary 26, 2025 | au.investing.comImugene Secures Indian Patent for CF33 Oncolytic VirotherapyFebruary 26, 2025 | tipranks.comImugene Expands Capital with New Securities QuotationFebruary 21, 2025 | tipranks.comImugene Limited Issues Unquoted Equity Securities to Boost GrowthFebruary 21, 2025 | tipranks.comImugene Limited Announces Change in Director’s InterestFebruary 21, 2025 | tipranks.comBiocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapyFebruary 18, 2025 | msn.comASX Market Update: IT stocks lead Aussie bourse higher | Feb 14, 2025February 14, 2025 | msn.comImugene’s Azer-cel therapy achieves two more complete responses in patients with B-cell lymphoma blood cancerFebruary 13, 2025 | au.investing.comImugene’s Azer-cel Shows Promising Results in CAR-T Phase 1b TrialFebruary 13, 2025 | tipranks.comImugene Limited Announces Quotation of New Securities on ASXJanuary 29, 2025 | tipranks.comImugene Limited Adjusts Securities Portfolio with Cessation of Restricted Stock UnitsJanuary 29, 2025 | tipranks.comImugene Secures A$20 Million to Advance Clinical TrialsJanuary 28, 2025 | tipranks.comImugene Limited Issues Convertible Notes and Warrants to Fund Cancer Immunotherapy EffortsJanuary 27, 2025 | tipranks.com Get Imugene News Delivered to You Automatically Sign up to receive the latest news and ratings for IMU and its competitors with MarketBeat's FREE daily newsletter. Email Address IMU Media Mentions By Week IMU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMU News Sentiment▼0.911.07▲Average Medical News Sentiment IMU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMU Articles This Week▼41▲IMU Articles Average Week Get Imugene News Delivered to You Automatically Sign up to receive the latest news and ratings for IMU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Enliven Therapeutics News Praxis Precision Medicines News Structure Therapeutics News Ardelyx News BGM Group News Avadel Pharmaceuticals News Dyne Therapeutics News Akebia Therapeutics News Collegium Pharmaceutical News Zymeworks News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:IMU) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imugene Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Imugene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMU Stock Alerts